Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device.
Zietkiewicz M, Garlicki M, Domagala J, et al.
J Thorac Cardiovasc Surg 2002;123(2):384-385.
NATA Rating :
Review by :
This is a case report on effective hemostasis achieved after administering recombinant factor VIIa in a patient who had severe intra-operative and post-operative bleeding and severe hemostatic disturbances following cardiac valve surgery and insertion of left ventricular assist device. Two relatively small doses of rFVIIa were used (20 and 30 mg/L) and there was no evidence for thrombosis or platelet aggregation. Bleeding was controlled effectively, but the patient died after 7 days due to tension pneumothorax.
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.